The Chief Executive Officer of emerging growth drug development company Corbus Pharmaceuticals Holdings, Inc. has been invited to present at the Virtual Investor Conferences, a live and interactive online event that will take place on Thursday, December 4 at 11:30 a.m. EST. Yuval Cohen, Ph.D., CEO of Corbus, will represent the company and present on the development and commercialization of its lead candidate Resunab for the treatment of rare and life-threatening inflammatory and fibrotic diseases such as scleroderma.
Cohen will offer updates on the company’s work and progress regarding its drug development efforts and will outline near-term clinical development milestones for Resunab. The medication is a novel, synthetic, oral specialized, pro-resolving mediator drug with unique anti-inflammatory and anti-fibrotic activity, which is expected to be become a viable treatment for both diffuse scleroderma and cystic fibrosis.
The Virtual Investor Conferences, created in 2010 by the BetterInvesting (NAIC) and the PRNewswire, are a series of monthly online and interactive forums that invite companies to present their ongoing projects directly to investors through a graphically-enhanced platform in order to enhance communication and foster eventual partnerships.
The conferences will be available and open in real-time at VirtualInvestorConferences.com, and the participants will also be able to ask questions online during the presentation in the virtual presentation hall or in Corbus Pharmaceuticals’ “virtual trade booth.” In addition, the CEO’s presentation will also remain available in the on-demand archive of the website for 90 days. Corbus Pharmaceuticals will embed a link for the presentation on their website as well.
In addition, Cohen and Corbus Pharmaceuticals were recently invited to present their developments of Resunab at the Leerink Partners Rare Disease Roundtable, an event organized by specialty healthcare investment bank Leerink Partners, to discuss rare diseases. The event took place October 1st in New York City, and Cohen presented the results of pre-clinical and phase 1 clinical trials of the drug, which revealed the drug’s safety profile as well as its capacity to bind the CB2 receptor of immune cells and trigger the process of “inflammatory resolution,” disabling chronic inflammation. The company is scheduled to begin its phase 2a clinical trials in 2015.